Amgen today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO ® compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia were published in The Journal of the American Medical Association . 1 BLINCYTO …
Amgen (NASDAQ:AMGN) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO ® (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published in The Journal of the American Medical Association (JAMA) . 1
Share this article
Share this article
THOUSAND OAKS, Calif., March 2, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that data from a multicenter, randomized Phase 3 study evaluating the efficacy, safety and tolerability of BLINCYTO
® (blinatumomab) compared with consolidation chemotherapy before allogeneic hematopoietic stem cell transplantation (alloHSCT) in pediatric patients with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL) were published in
The Journal of the American Medical Association (JAMA).
1
BLINCYTO demonstrated significantly prolonged event-free survival (events were defined by relapse, death, second malignancy, or failure to achieve complete remission) compared with chemotherapy. After a median of 22.4 months follow-up, 69% of patients treated with BLINCYTO were alive and event-free compared with 43% of patients treated with chemotherapy. Additionally, following treatment with BLINCYTO, 93% of patients with MRD at baseli
90-day vaginal ring may effectively prevent both HIV and pregnancy medicaldialogues.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicaldialogues.in Daily Mail and Mail on Sunday newspapers.
Vaginal Ring Holds Potential in Preventing HIV and Pregnancy by Angela Mohan on January 27, 2021 at 3:23 PM
Vaginal ring containing Dapivirine and levonorgestrel delivered sustained levels of drugs when used continuously for 90 days, levels likely sufficient to serve dual purpose for protecting against both HIV and unwanted pregnancy.
Results of the Phase I study of the 90-day dual-purpose ring are being presented at the HIV Research for Prevention (HIVR4P) Virtual Conference, or HIVR4P Virtual, which is taking place over the course of four days.
The study, MTN-044/IPM 053/CCN019, was conducted by researchers from the National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN) in collaboration with NIH s Contraceptive Clinical Trials Network (CCTN) and is the first to evaluate the ring s use, as intended, for 90 days.
E-Mail
PITTSBURGH, 26 January 2021 - A vaginal ring containing the antiretroviral drug dapivirine and the contraceptive hormone levonorgestrel delivered sustained levels of each drug when used continuously for 90 days - levels likely sufficient to serve its dual purpose for protecting against both HIV and unwanted pregnancy, according to findings of a new study.
Results of the Phase I study of the 90-day dual-purpose ring are being presented at the HIV Research for Prevention (HIVR4P) Virtual Conference, or HIVR4P // Virtual, which is taking place over the course of four days: Jan. 27-28 and Feb. 3-4.
The study, MTN-044/IPM 053/CCN019, was conducted by researchers from the National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN) in collaboration with NIH s Contraceptive Clinical Trials Network (CCTN) and is the first to evaluate the ring s use, as intended, for 90 days. In an earlier first-in-human study (MTN-030/IPM 041), also conducted by the MTN, women use